寶馨科技(002514.SZ):安徽懷遠一期2GW高效異質結電池及組件產線設備已陸續進場調試
格隆匯11月21日丨寶馨科技(002514.SZ)於2023年11月21日接受特定對象調研,就“請介紹公司異質結項目目前進展”,公司回覆稱,目前公司投資建設的安徽懷遠一期2GW高效異質結電池及組件產線設備已陸續進場調試,同時在有序推進懷遠二期先期2GW以及內蒙古鄂托克旗2GW光伏異質結電池及組件項目。公司在推進光伏異質結產線的落地和穩步擴產步伐,保障產線產量、產品質量以及降本增效的同時,優化上游供應鏈和強化下游海外市場的開拓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.